Galera Therapeutics Company Description

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer.

The company’s lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC).

It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC).

The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Galera Therapeutics, Inc.

Country	United States
Founded	2012
Industry	Biotechnology
Sector	Healthcare
Employees	3
CEO	John Sorensen

Contact Details

Address: 101 Lindenwood Drive Malvern, Pennsylvania 19355 United States
Phone	610 725 1500
Website	galeratx.com

Stock Details

Ticker Symbol	GRTXD
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
John Sorensen	Chief Executive Officer